Xbrane Biopharma AB (ST:XBRANE) — Market Cap & Net Worth
Market Cap & Net Worth: Xbrane Biopharma AB (XBRANE)
Xbrane Biopharma AB (ST:XBRANE) has a market capitalization of $22.84 Million (Skr212.24 Million) as of June 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #24697 globally and #490 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xbrane Biopharma AB's stock price Skr10.30 by its total outstanding shares 20605348 (20.61 Million). Review debt load of Xbrane Biopharma AB to assess the company's total debt and financial obligations.
Xbrane Biopharma AB Market Cap History: 2016 to 2026
Xbrane Biopharma AB's market capitalization history from 2016 to 2026. Data shows change from $85.14 Million to $22.84 Million (-10.78% CAGR).
Xbrane Biopharma AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xbrane Biopharma AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.15x
Xbrane Biopharma AB's market cap is 0.15 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.18x
Xbrane Biopharma AB's market cap is 0.18 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $85.14 Million | $2.49 Million | -$33.29 Million | 34.19x | N/A |
| 2017 | $138.22 Million | $20.77 Million | -$44.94 Million | 6.65x | N/A |
| 2018 | $96.49 Million | $112.95 Million | -$13.24 Million | 0.85x | N/A |
| 2019 | $76.72 Million | $600.00K | -$167.47 Million | 127.87x | N/A |
| 2020 | $165.87 Million | $6.82 Million | -$226.79 Million | 24.32x | N/A |
| 2021 | $232.39 Million | $11.53 Million | -$191.01 Million | 20.15x | N/A |
| 2022 | $182.05 Million | $57.62 Million | -$172.23 Million | 3.16x | N/A |
| 2023 | $22.17 Million | $238.73 Million | -$388.17 Million | 0.09x | N/A |
| 2024 | $356.57K | $198.70 Million | -$266.22 Million | 0.00x | N/A |
| 2025 | $22.62 Million | $152.35 Million | $127.24 Million | 0.15x | 0.18x |
Competitor Companies of XBRANE by Market Capitalization
Companies near Xbrane Biopharma AB in the global market cap rankings as of June 19, 2026.
Key companies related to Xbrane Biopharma AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Xbrane Biopharma AB Historical Marketcap From 2016 to 2026
Between 2016 and today, Xbrane Biopharma AB's market cap moved from $85.14 Million to $ 22.84 Million, with a yearly change of -10.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr22.84 Million | +0.98% |
| 2025 | Skr22.62 Million | +6243.28% |
| 2024 | Skr356.57K | -98.39% |
| 2023 | Skr22.17 Million | -87.82% |
| 2022 | Skr182.05 Million | -21.66% |
| 2021 | Skr232.39 Million | +40.11% |
| 2020 | Skr165.87 Million | +116.18% |
| 2019 | Skr76.72 Million | -20.49% |
| 2018 | Skr96.49 Million | -30.19% |
| 2017 | Skr138.22 Million | +62.35% |
| 2016 | Skr85.14 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Xbrane Biopharma AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.84 Million USD |
| MoneyControl | $22.84 Million USD |
| MarketWatch | $22.84 Million USD |
| marketcap.company | $22.84 Million USD |
| Reuters | $22.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adu… Read more